Literature DB >> 2242291

Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats.

W S Jee1, S Mori, X J Li, S Chan.   

Abstract

To assess the efficacy of prostaglandin E2 (PGE2) in augmenting cortical bone mass, graded doses of PGE2 were subcutaneously administered for 30 days to seven-month old sham-ovariectomized (SHAM) and ovariectomized (OVX) rats. Both groups were operated at three months of age. Histomorphometric analyses of double fluorescent labeled tibial shafts were performed on basal control, OVX, and SHAM rats treated with 0, 0.3, 1, 3, and 6 mg PGE2/kg/d for 30 days. Baseline aging data showed increased cortical tissue and cortical bone area and reduced bone formation parameters at the periosteal and endocortical bone envelopes between three and eight months of age. The tibial shafts of OVX rats compared to SHAM controls showed elevated periosteal mineral apposition rate and endocortical bone formation parameters. PGE2 administration to OVX and SHAM rats increased cortical bone by the addition of new circumferential bone on the endocortical and periosteal surfaces, as well as woven cancellous bone in the marrow region. Stimulated osteoblastic recruitment and activity enhanced bone formation at all bone surfaces. The new bone was both lamellar and woven in nature. PGE2 treatment also activated intracortical bone remodeling (not seen in untreated eight-month old rats), creating a porous cortex. Thus, PGE2 administration activated cortical bone modeling in the formation mode (A----F), as well as intracortical bone remodeling (A----R----F). PGE2 administration to OVX rats resulted in more intracortical bone remodeling, periosteal bone formation, and new cancellous bone production than observed in PGE2 treated controls. The findings that PGE2 administration to OVX and intact female rats increases cortical bone mass, coupled with observations that mouse, rat, dog, and man respond similarly to PGE2, suggest that PGE2 administration may be useful in the prevention and treatment of postmenopausal osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242291     DOI: 10.1016/8756-3282(90)90078-d

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  28 in total

1.  In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.

Authors:  S Hu; C C Liu; G Chen; T Willett; R N Young; M D Grynpas
Journal:  Osteoporos Int       Date:  2015-08-14       Impact factor: 4.507

Review 2.  Toward a cure for osteoporosis: reversal of excessive bone fragility.

Authors:  C H Turner
Journal:  Osteoporos Int       Date:  1991-10       Impact factor: 4.507

3.  Release of prostaglandin E(1) from N-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells.

Authors:  Huaizhong Pan; Jihua Liu; Yuanyi Dong; Monika Sima; Pavla Kopecková; Maria Luisa Brandi; Jindrich Kopecek
Journal:  Macromol Biosci       Date:  2008-07-07       Impact factor: 4.979

4.  Conjugated linoleic acids alter bone fatty acid composition and reduce ex vivo prostaglandin E2 biosynthesis in rats fed n-6 or n-3 fatty acids.

Authors:  Y Li; B A Watkins
Journal:  Lipids       Date:  1998-04       Impact factor: 1.880

Review 5.  Mechanotransduction and the functional response of bone to mechanical strain.

Authors:  R L Duncan; C H Turner
Journal:  Calcif Tissue Int       Date:  1995-11       Impact factor: 4.333

Review 6.  Osteocytes, strain detection, bone modeling and remodeling.

Authors:  L E Lanyon
Journal:  Calcif Tissue Int       Date:  1993       Impact factor: 4.333

7.  Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats.

Authors:  V Shen; R Birchman; R Xu; M Otter; D Wu; R Lindsay; D W Dempster
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Effects of low-dose long-term sodium fluoride preventive treatment on rat bone mass and biomechanical properties.

Authors:  Y Jiang; J Zhao; R Van Audekercke; J Dequeker; P Geusens
Journal:  Calcif Tissue Int       Date:  1996-01       Impact factor: 4.333

9.  Exogenous prostacyclin, but not prostaglandin E2, produces similar responses in both G6PD activity and RNA production as mechanical loading, and increases IGF-II release, in adult cancellous bone in culture.

Authors:  S C Rawlinson; S Mohan; D J Baylink; L E Lanyon
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

10.  Increased bone growth by local prostaglandin E2 in rats.

Authors:  R S Yang; T K Liu; S Y Lin-Shiau
Journal:  Calcif Tissue Int       Date:  1993-01       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.